%0 Journal Article
%T Evaluating the evolving evidence: The challenges of  molecular-targeted therapy in management of gastric cancer
%A Yasar Albushra Abdul Rahiem Ahmed
%A Mohamed Ali
%J Open Journal of Gastroenterology
%P 6-15
%@ 2163-9469
%D 2014
%I Scientific Research Publishing
%R 10.4236/ojgas.2014.41002
%X <p style=\"text-align:justify;\">
	<span style=\"font-size:10.0pt;\"><span style=\"font-family:Verdana;\">Over the past decade, </span><span style=\"font-family:Verdana;\">a multitude of molecular
targeted agents have been explored in the treatment of advanced metastatic
gastric. Recent advances in molecular signaling pathways that are dysregulated in
gastric cancer lead to the development of new targeted therapies for the
treatment of advanced and metastatic gastric cancer. The addition of trastuzumab
to first-line chemotherapy is now a standard of care for the treatment of Human
epidermal growth factor receptor (HER2-) positive advanced or metastatic
disease, and other HER2-targeted therapies are in late-stage clinical
development. Findings from recent major clinical trials provide important
insight into the future of metastatic gastric cancer management, which may
include the use of anti-angiogenesis, Mesenchymal epithelial transition factor
(MET) and Hedgehog Pathways Inhibitortherapy across multiple treatment lines,
in the salvage setting, and as part of novel regimens in combination with other
targeted agents.</span></span><span style=\"font-size:10.0pt;\"></span> 
</p>
<p style=\"text-align:justify;\">
	<span style=\"font-family:Verdana;\"> </span> 
</p>
%K Gastric Cancer
%K Targeted Therapy
%K Trastuzumab
%K HER2-
%U http://www.scirp.org/journal/PaperInformation.aspx?PaperID=41874